| Sarah Ann Crowbridge, RN | |
|
480 Mckinley Street, Amherst, WI 54406 | |
| (715) 824-2346 | |
| Not Available |
| Full Name | Sarah Ann Crowbridge |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 480 Mckinley Street, Amherst, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245402957 | NPI | - | NPPES |
| 38337600 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Ann Crowbridge, RN 480 Mckinley Street, Amherst, WI 54406 Ph: (718) 824-2346 | Sarah Ann Crowbridge, RN 480 Mckinley Street, Amherst, WI 54406 Ph: (715) 824-2346 |
News Archive
BioMarin Pharmaceutical Inc. today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with mucopolysaccharidosis IVA.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while Amgen/Stiefel/Pfizer's Enbrel is the most popular biologic across all lines of therapy for psoriasis treatment in newly diagnosed patients, Abbott's Humira is gaining increasing use as a first-line biologic at Enbrel's expense.
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.
The National Nanotechnology Initiative (NNI) today published the report from the workshop, "Stakeholder Perspectives on Perception, Assessment, and Management of the Potential Risks of Nanotechnology" (R3 Workshop), which was held September 10-11, 2013, in Washington, D.C.
Astellas Pharma Inc. today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Astellas' proposed acquisition of OSI Pharmaceuticals Inc. has expired.
› Verified 1 days ago
Ms. Teresa Rose Albrecht, R.N. Registered Nurse Medicare: Not Enrolled in Medicare Practice Location: 9528 Sumac Cir, Amherst, WI 54406 Phone: 715-824-2596 |